Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice

Genes and Development

Volumn 27, Issue 5, 2013, Pages 504-513

  Soucek, Laura ^a,b,c   Whitfield, Jonathan R ^a,b,c   Sodir, Nicole M ^a,d   Massó Vallés, Daniel ^b,c   Serrano, Erika ^b,c   Karnezis, Anthony N ^a   Swigart, Lamorna Brown ^a   Evan, Gerard I ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cancer therapy; Lung cancer; Mouse model; Myc

Indexed keywords

K RAS PROTEIN; MYC PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN FAMILY; TUMOR REGRESSION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS; LUNG NEOPLASMS; MICE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874835799     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.205542.112     Document Type: Article

References (25)

1. Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, Schmitt CA. (2007). FoxO transcription factors suppress Mycdriven lymphomagenesis via direct activation of Arf. Genes Dev 21: 2775-2787.
2. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI. (2005). Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718-726.
3. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
4. Grabacka M, Pierzchalska M, Reiss K. (2010). Peroxisome proliferator activated receptor a ligands as anti-cancer drugs targeting mitochondrial metabolism. Curr Pharm Biotechnol PMID: 21133850.
5. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes & Dev 15: 3243-3248.
6. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. (2005). The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280-10288.
7. Ji J, Sundquist K, Sundquist J. (2012). Cancer incidence in patients with polyglutamine diseases: A population-based study in Sweden. Lancet Oncol 13: 642-648.
8. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, et al. (2010). Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567-571.
9. Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R, et al. (2005). Mouse models of human non-small-cell lung cancer: Raising the bar. Cold Spring Harb Symp Quant Biol 70: 241-250.
10. Larsson LG, Henriksson MA. (2010). The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 316: 1429-1437.
11. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, Kong AN. (2008). Activation of Nrf2-antioxidant signaling attenuates NFkBinflammatory response and elicits apoptosis. Biochem Pharmacol 76: 1485-1489.
12. Nance MA, Mathias-Hagen V, Breningstall G, Wick MJ, McGlennen RC. (1999). Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease. Neurology 52: 392-394.
13. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et al. (2010). Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 24: 837-852.
14. Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, et al. (2012). Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell 150: 563-574.
15. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S. (2011). The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS ONE 6: e22284.
16. Singh M, Lima A, Molina R, Hamilton P, Clermont AC, Devasthali V, Thompson JD, Cheng JH, Bou Reslan H, Ho CC, et al. (2010). Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol 28: 585-593.
17. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. (2011). Endogenous Myc maintains the tumor microenvironment. Genes Dev 25: 907-916.
18. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. (1998). Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 17: 2463-2472.
19. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, Nasi S. (2002). Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62: 3507-3510.
20. Soucek L, Nasi S, Evan GI. (2004). Omomyc expression in skin prevents Myc-induced papillomatosis. Cell Death Differ 11: 1038-1045.
21. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
22. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. (2005). An oncogenic KRAS2 expression signature identified by crossspecies gene-expression analysis. Nat Genet 37: 48-55.
23. Tachibana K, Yamasaki D, Ishimoto K, Doi T. (2008). The role of PPARs in cancer. PPAR Res 2008: 102737.
24. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, et al. (2004). Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5: 375-387.
25. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.